Originally developed in collaboration with the American Red Cross, PPPS™ employs powerful affinity separation materials in a multi-step process to extract and purify commercially valuable plasma proteins in high yield.
Prometic exploits a proprietary platform derived from the use of PBL’s affinity technology which enables the PPPS™ multi-product sequential purification process, facilitating highly efficient extraction and purification of therapeutic proteins from human plasma.
After years of refining PPPS™ Prometic successfully developed a robust and scalable manufacturing process which was launched at its plasma purification facility, PrometicBioProduction Inc., in Laval, Quebec, in late 2013.
What makes the process unique and cutting edge is down to the efficient targeting and removal of multiple high-value proteins from a single plasma sample at unprecedented activity levels.
This enables Prometic to develop best-in-class plasma-derived therapeutics which will address some unmet medical conditions and rare diseases in both established and emerging markets.